3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Testicular Neoplasms
30
Testicular Germ Cell Tumor
17
Prostatic Neoplasms
13
Wilms Tumor
12
Teratoma
12
Ovarian Neoplasms
11
Kidney Neoplasms
9
Seminoma
8
Endodermal Sinus Tumor
8
Sarcoma
7
Neuroectodermal Tumors, Primitive, Peripheral
7
Central Nervous System Neoplasms
7
Carcinoma, Embryonal
7
Ovarian Germ Cell Cancer
6
Carcinoma, Renal Cell
6
Urinary Bladder Neoplasms
4
Osteosarcoma
4
Neuroblastoma
4
Neoplasms
4
Melanoma
4
Medulloblastoma
4
Small Cell Lung Carcinoma
3
Rhabdoid Tumor
3
Retinoblastoma
3
Optic Nerve Glioma
3
Neoplasms, Germ Cell and Embryonal
3
Lung Neoplasms
3
Hepatoblastoma
3
Breast Neoplasms
3
Astrocytoma
3
Interventions
enzalutamide
7
Abiraterone Acetate
4
abiraterone
3
Prednisone
3
Docetaxel
3
sapanisertib
1
relugolix
1
pembrolizumab
1
onvansertib
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
abemaciclib
1
Prednisolone
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-Resistant Prostate Cancer
×
Etoposide
×
Genitourinary
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled